Results 241 to 250 of about 139,370 (300)

Position Statement on Antiplatelet Therapy for East Asians With Coronary Artery Disease: 2025 Update. [PDF]

open access: yesJACC Asia
Gong Y   +19 more
europepmc   +1 more source

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 955-966, April 2026.
In the phase I/IIa GOING trial, an add‐on strategy with regorafenib followed by nivolumab showed a manageable safety profile and meaningful clinical activity in second‐line hepatocellular carcinoma, with a median overall survival of 25 months and 45% three‐year survival in sorafenib‐experienced patients.
Marco Sanduzzi‐Zamparelli   +24 more
wiley   +1 more source

Utilization and Outcomes of Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement (TAVR)

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Agam Bansal   +5 more
doaj   +1 more source

Retinal Vascular Occlusion in Patients on Anticoagulation and Antiplatelet Therapy: a Case Report and Comprehensive Review. [PDF]

open access: yesMaedica (Bucur)
Madi M   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy